Form 4: Viking Therapeutics CEO Reports Equity Transactions

Viking Therapeutics CEO Brian Lian reported the acquisition of restricted stock units and stock options, alongside sales of shares to cover tax obligations.

Summary

• Brian Lian, President & CEO and Director of Viking Therapeutics, Inc. (VKTX), reported several transactions related to his beneficial ownership.
• On January 2, 2026, Lian acquired 78,400 shares of common stock as a restricted stock unit (RSU) award under the Issuer's 2024 Equity Incentive Plan, with one-third vesting annually from the grant date.
• Also on January 2, 2026, Lian acquired 224,080 shares of common stock from the vesting of performance restricted stock unit awards, granted on January 3, 2023 (33.33% vested) and January 3, 2025 (1.665% vested), upon achievement of non-financial performance goals.
• On January 2, 2026, Lian was granted 176,300 stock options with an exercise price of $35.42, vesting 25% annually from the grant date.
• On January 5, 2026, Lian sold a total of 233,409 shares of common stock in multiple transactions at weighted-average prices ranging from $32.2907 to $35.0661.
• These sales were non-discretionary and solely to satisfy tax withholding obligations in connection with the vesting of certain restricted stock unit awards.
• Following these reported transactions, Lian beneficially owns 2,499,291 shares of common stock and 176,300 stock options.

Sentiment

Score: 7

Explanation: The filing details routine insider transactions related to equity compensation, including grants of new awards and sales to cover tax obligations. The grants indicate continued alignment of management interests with shareholders, and the sales are a standard, non-discretionary event following vesting. This is generally a neutral to slightly positive signal, reflecting ongoing compensation practices and performance.

Positives

• The grant of new restricted stock units (78,400 shares) and stock options (176,300 shares) indicates continued incentive alignment between management and shareholders.
• The vesting of 224,080 performance restricted stock units suggests the achievement of non-financial performance goals by the company.

Negatives

• A total of 233,409 shares were sold, reducing the direct beneficial ownership of the CEO, although these sales were for tax withholding purposes.

Future Outlook

The restricted stock unit award of 78,400 shares will vest one-third on each one-year anniversary of the grant date. The 176,300 stock options will vest 25% on each anniversary of the grant date.

Industry Context

NA

Stakeholder Impact

• Shareholders: The grants of new equity awards align the CEO's interests with long-term shareholder value. The sales for tax purposes are a common occurrence and do not typically signal a change in company fundamentals or management's confidence.

Next Steps

• One-third of the 78,400 RSU shares will vest on each one-year anniversary of the grant date.
• 25% of the 176,300 stock options will vest on each anniversary of the grant date.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to equity compensation, including grants of restricted stock units and stock options, and non-discretionary sales to cover tax withholding. These transactions are common and do not indicate a change in the company's fundamental outlook or the insider's confidence beyond standard compensation practices. Therefore, it does not warrant a change in investment recommendation.

Keywords

Viking Therapeutics, VKTX, Brian Lian, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Beneficial Ownership